Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma

This study is testing a combination of two drugs — sintilimab (an immunotherapy) and a biosimilar version of bevacizumab (a drug that cuts off blood supply to tumors) — given before surgery in people with liver cancer (hepatocellular carcinoma, or HCC) that has not yet spread but is larger than what standard transplant guidelines typically allow. The goal is to shrink the tumor enough to make surgery safer and more successful. **You may be eligible if...** - You are 18 or older - You have liver cancer confirmed by imaging or pathology, and it is considered resectable (can be surgically removed) - You have not received any prior treatment for liver cancer - Your liver function is well-preserved (Child-Pugh class A) - Your expected survival is greater than 6 months and you are in generally good health **You may NOT be eligible if...** - You have a rare liver cancer type (cholangiocarcinoma, fibrolamellar, or sarcomatoid) - You have had a liver transplant or a history of hepatic encephalopathy (brain fogging from liver failure) - You have had recent serious bleeding from esophageal or gastric varices (enlarged veins) - You have uncontrolled high blood pressure or blood clotting problems - You had a major blood vessel event (heart attack, stroke, pulmonary embolism) in the last 6 months Talk to your doctor to see if this trial is right for you.